{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"4.040","rs_stock_flag":false,"fiscal_year_end":"2024年12月31日","hist_closedate":"2025年9月25日","replication_method":null,"amt_os":"571,325,668","primaryexch":"香港交易所","ric":"2511.HK","product_subtype":null,"db_updatetime":"2025年9月28日08:06","mkt_cap_u":"B","am_u":"M","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":0.0,"inline_upper_strike_price":"","sedol":"BPSHQX2","am":"3.32","iv":"","ew_strike":"","as":"3.900","geographic_focus":null,"incorpin":"開曼群島","etp_baseCur":null,"ew_amt_os":"","bd":"3.860","registrar":"香港中央證券登記有限公司","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"500","update_time":"2025-09-28 00:06:03.0","lo52":"0.780","shares_issued_date":"2025年8月31日","premium":"","strike_price_ccy":null,"yield":"","vo_u":"K","base_currency":null,"coupon":"","expiry_date":"","chairman":"劉利平","underlying_ric":"2511.HK","hi52":"4.700","issuer_name":"君聖泰醫藥 - B","h_share_flag":false,"ew_sub_per_from":"","div_yield":"","interest_payment_date":"-","updatetime":"2025年9月26日16:08","aum_date":"","lo":"3.810","mkt_cap":"2.22","f_aum_hkd":null,"ew_sub_per_to":"","ls":"3.900","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"醫療保健業 - 藥品及生物科技","ew_desc":null,"inception_date":"","nc":"-0.120","aum":"","issued_shares_class_B":null,"vo":"846.00","secondary_listing_flag":false,"listing_date":"2023年12月22日","issued_shares_class_A":null,"as_at_label":"截至","ew_amt_os_dat":"","nm":"君聖泰醫藥 - B","nm_s":"君聖泰醫藥－Ｂ","sym":"2511","inline_lower_strike_price":"","listing_category":"主要上市","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.010","strike_price":"","summary":"君聖泰醫藥是一家生物製藥公司，專注於就代謝及消化系統疾病的治療發現、開發及商業化多功能及多標靶療法。該公司自主開發了多個候選產品的產品管線，涵蓋代謝和消化疾病的多種適應症，其中部分產品處於臨床階段。該公司的核心產品HTD1801（小檁鹼熊去氧膽酸鹽）是一種新分子實體，作為腸肝抗炎代謝調節劑，靶向調節對人體代謝過程中至關重要的多個通路，包括與代謝及消化系統疾病相關的路徑。該公司在美國、中國大陸、香港和澳洲開展業務。","op":"4.030","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"藥品","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"香港灣仔<br/>皇后大道東248號<br/>大新金融中心<br/>40樓","pc":"-2.99","days_to_expiry":null,"underlying_code":null,"pe":"","eps_ccy":"RMB","hdr":false,"launch_date":"","hc":"4.020","isin":"KYG4568L1023","moneyness":""}},"qid":"1759074491924"}
